Musredo (molidustat) / Bayer 
Welcome,         Profile    Billing    Logout  
 6 Diseases   1 Trial   1 Trial   176 News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Musredo (molidustat) / Bayer
2021-006895-17: Combination therapy of the PHD inhibitor molidustat with the IDH1 inhibitor ivosidenib in patients with relapsed/refractory AML or MDS/AML with IDH1 mutation.

Not yet recruiting
1/2
27
Europe
Tablet, TIBSOVO®, MUSREDO®
Hannover Medical School, German Cancer Aid
Adult patients with relapsed or refractory IDH1-mutated AML or relapsed/refractory MSD/AML with 10-19% bone marrow blasts at initial diagnosis and at screening (ECOG 0-2) after at least one prior line of treatment (including intensive chemotherapy,at least 2 cycles of hypomethylating agents or low-dose cytarabine, and alloHCT),who are not eligible for intensive chemotherapy including alloHCT can be recruited and will be treated with the PHD inhibitor molidustat and the IDH1 inhibitor ivosidenib., The clinical trial will investigate whether combination therapy of molidustat and ivosidenib is safe and can improve treatment outcomes in patients suffering from IDH1-mutated AML or MDS., Diseases [C] - Cancer [C04]
 
 
NCT04899661: A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia

Active, not recruiting
N/A
1081
Japan
Molidustat (Musredo, BAY85-3934)
Bayer
Renal Anemia
06/27
09/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Musredo (molidustat) / Bayer
2021-006895-17: Combination therapy of the PHD inhibitor molidustat with the IDH1 inhibitor ivosidenib in patients with relapsed/refractory AML or MDS/AML with IDH1 mutation.

Not yet recruiting
1/2
27
Europe
Tablet, TIBSOVO®, MUSREDO®
Hannover Medical School, German Cancer Aid
Adult patients with relapsed or refractory IDH1-mutated AML or relapsed/refractory MSD/AML with 10-19% bone marrow blasts at initial diagnosis and at screening (ECOG 0-2) after at least one prior line of treatment (including intensive chemotherapy,at least 2 cycles of hypomethylating agents or low-dose cytarabine, and alloHCT),who are not eligible for intensive chemotherapy including alloHCT can be recruited and will be treated with the PHD inhibitor molidustat and the IDH1 inhibitor ivosidenib., The clinical trial will investigate whether combination therapy of molidustat and ivosidenib is safe and can improve treatment outcomes in patients suffering from IDH1-mutated AML or MDS., Diseases [C] - Cancer [C04]
 
 
NCT04899661: A Study to Learn More About the Long-term Safety and Effectiveness of Molidustat as a Treatment for Japanese Men and Women With Renal Anemia

Active, not recruiting
N/A
1081
Japan
Molidustat (Musredo, BAY85-3934)
Bayer
Renal Anemia
06/27
09/27

Download Options